AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35100339 — intervention group
Group type: COMPARATOR
Intervention: Standard lenalidomide maintenance therapy started at 3 months after ASCT for all patients.
Number of subjects: 20
Study 35100411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperferritinemia (≥500 ng/mL) in 46 patients (26%)
Number of subjects: 174
Study 35100411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperferritinemia (≥250 ng/mL) in 90 patients (52%)
Number of subjects: 174
Study 35100411 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP patients (n = 174)
Number of subjects: 174
Study 35100411 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls without infection, n = 50, median ferritin level 102.8 ng/mL (IQR 53.5-185.7)
Number of subjects: 174
Study 35100444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (1,200 mg every 4 weeks)
Number of subjects: 0
Study 35100444 — intervention group
Group type: COMPARATOR
Intervention: Low-dose gantenerumab
Number of subjects: 0
Study 35100444 — intervention group
Group type: COMPARATOR
Intervention: High-dose aducanumab
Number of subjects: 0
Study 35100444 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab
Number of subjects: 0
Study 35100459 — intervention group
Group type: EXPERIMENTAL
Intervention: ravulizumab
Number of subjects: 0
Study 35100459 — intervention group
Group type: COMPARATOR
Intervention: eculizumab
Number of subjects: 0
Study 35100692 — intervention group
Group type: EXPERIMENTAL
Intervention: No changes in the CCND/CDK pathway
Number of subjects: 390
Study 35100692 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrations of genes in CCND/CDK, FGFR/FGF, and PI3K/AKT pathways
Number of subjects: 390
Study 35100697 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy plus anti-EGFR therapy (specifics not available)
Number of subjects: 0
Study 35100750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute suicidality presentation
Number of subjects: 41
Study 35100750 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department length of stay (LOS)
Number of subjects: 41
Study 35100750 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-9 (PHQ-9) scores
Number of subjects: 41
Study 35100923 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of canonical babbling status based on CBR ≥ 0.15 by Speech Language Therapists (SLTs)
Number of subjects: 484
Study 35100923 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of CBR and total number of syllables by SLTs
Number of subjects: 484
Study 35101049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/sqm
Number of subjects: 74
Study 35101049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/sqm
Number of subjects: 74
Study 35101049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 or 25 mg/sqm)
Number of subjects: 74
Study 35101117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 97
Study 35101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 751
Study 35101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 751
Study 35101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 751
Study 35101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-lipid lowering therapies (LLT)
Number of subjects: 751
Study 35101175 — intervention group
Group type: COMPARATOR
Intervention: Non-high-income countries
Number of subjects: 751
Study 35101540 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated residual quantitative flow ratio (QFR)
Number of subjects: 2146
Study 35101540 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated residual QFR-guided strategy
Number of subjects: 2146
Study 35101540 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided strategy
Number of subjects: 2146
Study 35101772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mos1.Gag and Mos2.Gag virus-like particle (VLP) formation
Number of subjects: 0
Study 35101772 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-expression of Mos1.Gag and Mos2S.Env
Number of subjects: 0
Study 35101772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mos2S.Env-decorated VLPs
Number of subjects: 0
Study 35101886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care from diagnosis
Number of subjects: 764
Study 35101886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care after hospitalization
Number of subjects: 764
Study 35101886 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 764
Study 35101941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 2234
Study 35101941 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 2234
Study 35101941 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy vs. Chemotherapy
Number of subjects: 2234
Study 35102064 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 expression in thrombi
Number of subjects: 33
Study 35102064 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 expression in leukocytes
Number of subjects: 33
Study 35102064 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2, MMP-9, TIMP-1, TIMP-2 and EMMPRIN expression
Number of subjects: 33
Study 35102335 — intervention group
Group type: EXPERIMENTAL
Intervention: N-803 (IL-15 superagonist)
Number of subjects: 0
Study 35102497 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab (6 mg)
Number of subjects: 0
Study 35102497 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 0
Study 35102497 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 0
Study 35102780 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based kinaesthetic motor imagery training
Number of subjects: 0
Study 35103026 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administration
Number of subjects: 60
Study 35103026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 60
Study 35103026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative follow-up at 12 months
Number of subjects: 60
Study 35103026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative follow-up at 4 days
Number of subjects: 60
Study 35103064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus Obinutuzumab
Number of subjects: 32
Study 35103596 — intervention group
Group type: EXPERIMENTAL
Intervention: Single full-length VAR2CSA ectodomain variant
Number of subjects: 0
Study 35103596 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35103767 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial DCM defined by DCM in at least 1 first-degree relative; expanded familial DCM defined by DCM or either left ventricular enlargement or left ventricular systolic dysfunction without known cause in at least 1 first-degree relative.
Number of subjects: 1220
Study 35103767 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial DCM among Black probands compared to White probands.
Number of subjects: 1220
Study 35103767 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial DCM among Hispanic probands compared to non-Hispanic probands.
Number of subjects: 1220
Study 35103767 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded familial DCM.
Number of subjects: 1220
Study 35103767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk of DCM in first-degree relatives.
Number of subjects: 1220
Study 35103767 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM hazard in first-degree relatives of non-Hispanic Black probands compared to non-Hispanic White probands.
Number of subjects: 1220
Study 35103828 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kV 1.2 gI/s IDR protocol
Number of subjects: 1213
Study 35103828 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kV 0.96 gI/s IDR protocol
Number of subjects: 1213
Study 35103828 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kV protocols
Number of subjects: 1213
Study 35103828 — intervention group
Group type: COMPARATOR
Intervention: Standard 100-kV protocol
Number of subjects: 1213
Study 35104158 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cell transfer of enriched neoantigen-specific tumor-infiltrating lymphocytes (TIL) in combination with pembrolizumab (≤ 4 doses)
Number of subjects: 42
Study 35104158 — intervention group
Group type: EXPERIMENTAL
Intervention: TILs recognizing at least one immunogenic somatic mutation
Number of subjects: 42
Study 35104158 — intervention group
Group type: EXPERIMENTAL
Intervention: TILs isolated and grown in culture
Number of subjects: 42
Study 35105153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abre venous self-expanding stent system
Number of subjects: 200
Study 35105182 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 162
Study 35105182 — intervention group
Group type: COMPARATOR
Intervention: Noneptifibatide (Control)
Number of subjects: 162
Study 35105339 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability of body mass index (BMI)
Number of subjects: 4073
Study 35105339 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability of waist circumference (WC)
Number of subjects: 4073
Study 35105522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartech left ventricular partitioning device (LVPD) therapy
Number of subjects: 16
Study 35105572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-METRICS app
Number of subjects: 0
Study 35105576 — intervention group
Group type: EXPERIMENTAL
Intervention: Online volunteer-led group exercise
Number of subjects: 30
Study 35105587 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL repair and InternalBrace augmentation
Number of subjects: 90
Study 35105587 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction using hamstring autografts
Number of subjects: 90
Study 35105587 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study 35105633 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib as an adjunct to treatment-as-usual
Number of subjects: 0
Study 35105633 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an adjunct to treatment-as-usual
Number of subjects: 0
Study 35105642 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2
Number of subjects: 9
Study 35105647 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 0
Study 35105709 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 306
Study 35105722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 120 mg belimumab
Number of subjects: 334
Study 35105722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 334
Study 35105939 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting sphingosine-1-phosphate (S1P) in LAR tumors
Number of subjects: 330
Study 35105939 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamate as a therapeutic target
Number of subjects: 330
Study 35105942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 30
Study 35105942 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial state
Number of subjects: 30
Study 35106698 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa treatment in 5 patients with dystonia
Number of subjects: 7
Study 35106698 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI studies
Number of subjects: 7
Study 35106698 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Number of subjects: 7
Study 35106698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblotting for PEX16 protein
Number of subjects: 7
Study 35106709 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in lean body mass index (LBMI)
Number of subjects: 0
Study 35106709 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in fat mass
Number of subjects: 0
Study 35106743 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels
Number of subjects: 112
Study 35106743 — intervention group
Group type: COMPARATOR
Intervention: Salivary alpha-amylase levels
Number of subjects: 112
Study 35106962 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab monotherapy
Number of subjects: 14
Study 35107547 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 77
Study 35107547 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 77
Study 35107642 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Number of subjects: 31
Study 35107750 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg, 3 times daily)
Number of subjects: 114
Study 35107821 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to social distancing measures
Number of subjects: 1008
Study 35107821 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher occupational risk groups
Number of subjects: 1008
Study 35107821 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1008
Study 35107821 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR testing
Number of subjects: 1008
Study 35107821 — intervention group
Group type: COMPARATOR
Intervention: IgG serologic testing
Number of subjects: 1008
Study 35107821 — intervention group
Group type: COMPARATOR
Intervention: Both RT-PCR and IgG testing
Number of subjects: 1008
Study 35107848 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Number of subjects: 362
Study 35108379 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Number of subjects: 71
Study 35108379 — intervention group
Group type: EXPERIMENTAL
Intervention: SSc patients
Number of subjects: 71
Study 35108379 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 71
Study 35108395 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD patients with a previous diagnosis of IAs
Number of subjects: 2449
Study 35108395 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex, hypertension <35 years, smoking, and PKD1 genotype
Number of subjects: 2449
Study 35108395 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 2449
Study 35109669 — intervention group
Group type: EXPERIMENTAL
Intervention: CKmito overexpression in mice
Number of subjects: 27
Study 35109669 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic isoproterenol stimulation in CKmito-overexpressing mice
Number of subjects: 27
Study 35109669 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited CK capacity due to creatine substrate depletion in CKmito-overexpressing mice
Number of subjects: 27
Study 35109669 — intervention group
Group type: COMPARATOR
Intervention: Measurement of cardiac energetics and left ventricular remodeling
Number of subjects: 27
Study 35109696 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion
Number of subjects: 0
Study 35109806 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 399
Study 35109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting the MVPA recommendation (≥150 min/week)
Number of subjects: 2338
Study 35109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting the ST recommendation (≤8 h/day)
Number of subjects: 2338
Study 35109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting the sleep duration recommendation (7-9 h/day)
Number of subjects: 2338
Study 35109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting all three 24-hour movement guideline recommendations
Number of subjects: 2338
Study 35109819 — intervention group
Group type: COMPARATOR
Intervention: Being a woman
Number of subjects: 2338
Study 35109819 — intervention group
Group type: COMPARATOR
Intervention: Having a middle education level
Number of subjects: 2338
Study 35109819 — intervention group
Group type: COMPARATOR
Intervention: Having a high education level
Number of subjects: 2338
Study 35109819 — intervention group
Group type: COMPARATOR
Intervention: Being married
Number of subjects: 2338
Study 35109819 — intervention group
Group type: COMPARATOR
Intervention: Aged 50-64 years
Number of subjects: 2338
Study 35109900 — intervention group
Group type: EXPERIMENTAL
Intervention: Active feedback with in situ inter-professional simulation-training programme
Number of subjects: 15
Study 35109900 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive feedback with wide dissemination of Morbidity and Mortality conference results
Number of subjects: 15
Study 35109900 — intervention group
Group type: COMPARATOR
Intervention: Standard MMC (control arm)
Number of subjects: 15
Study 35109911 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ seeding activity in AD patients
Number of subjects: 218
Study 35109911 — intervention group
Group type: COMPARATOR
Intervention: Plasma Aβ seeding activity in NADD patients
Number of subjects: 218
Study 35109911 — intervention group
Group type: COMPARATOR
Intervention: Plasma Aβ seeding activity in NC subjects
Number of subjects: 218
Study 35109911 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ seeding activity
Number of subjects: 218
Study 35109911 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with cognitive performance
Number of subjects: 218
Study 35109911 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with conventional biomarkers
Number of subjects: 218
Study 35109924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus accumbens deep brain stimulation (NAcc-DBS)
Number of subjects: 6
Study 35110167 — intervention group
Group type: EXPERIMENTAL
Intervention: Group art therapy using clay (6 sessions of 1.5 hours each)
Number of subjects: 60
Study 35110167 — intervention group
Group type: COMPARATOR
Intervention: Control group (face-to-face interviews only)
Number of subjects: 60
Study 35110321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT angiography (CCTA)
Number of subjects: 60
Study 35110321 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up CCTA
Number of subjects: 60
Study 35110356 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA×CD3 bispecific antibody (bsAb)
Number of subjects: 0
Study 35110356 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activation
Number of subjects: 0
Study 35110384 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian group
Number of subjects: 1412
Study 35110384 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian group
Number of subjects: 1412
Study 35110417 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily with binimetinib 45 mg twice daily
Number of subjects: 23
Study 35110690 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial haploidentical stem cell transplant (haploidentical SCT)
Number of subjects: 19
Study 35110690 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent ratings of child's global health-related quality of life (HRQoL)
Number of subjects: 19
Study 35111295 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to aripiprazole with 2-week dual administration and tapering off original agents (fast: n=38, slow: n=41)
Number of subjects: 79
Study 35111295 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline chlorpromazine equivalent dose in ARE+ group (405.8 ± 225.8 mg)
Number of subjects: 79
Study 35111398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic infusion
Number of subjects: 30
Study 35111398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamps
Number of subjects: 30
Study 35111398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic clamp conditions with hyperglycemia
Number of subjects: 30
Study 35111828 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with LVEF ≤55%
Number of subjects: 1211
Study 35111828 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical correction of moderate AR for patients with LVEF 35-55%
Number of subjects: 1211
Study 35111828 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF as a prognostic factor
Number of subjects: 1211
Study 35112104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical venous thromboembolism (pVTE) prophylaxis
Number of subjects: 2006
Study 35112104 — intervention group
Group type: COMPARATOR
Intervention: No pVTE prophylaxis (control group)
Number of subjects: 2006
Study 35112128 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Gun Violence (GV)
Number of subjects: 225
Study 35112128 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental beliefs about guns and gun safety
Number of subjects: 225
Study 35112128 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for firearm injury prevention (FIP) counseling
Number of subjects: 225
Study 35112128 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on gun safety measures
Number of subjects: 225
Study 35112299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest therapy
Number of subjects: 887
Study 35112303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative phlebotomy
Number of subjects: 679
Study 35112306 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney failure-related encounters
Number of subjects: 237734
Study 35112306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular-related encounters
Number of subjects: 237734
Study 35112306 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-related encounters
Number of subjects: 237734
Study 35112306 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid-covered encounters
Number of subjects: 237734
Study 35112306 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall encounters
Number of subjects: 237734
Study 35112307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab in a treat-and-extend (TAE) regimen
Number of subjects: 75
Study 35112343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with kidney failure (KF)
Number of subjects: 607
Study 35112343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with recessive causal variants
Number of subjects: 607